Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Sarepta stock fell after it agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular ...

Key Takeaways The S&P 500 and Nasdaq reached record highs Monday, while the Dow advanced as well, in the wake of several strong earnings reports.Verizon Communications shares rose after the telecom ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety over Trumps looming tariff deadline. The Dow, S&P 500, and Nasdaq futures ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

The Dow Jones Industrial Average slipped on Friday (July 18) amid reports that US President Donald Trump is pushing for ...

Sarepta Therapeutics shares plunge over 37% as FDA weighs halting shipments of its key gene therapy, Elevidys, after patient ...

Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

PS Ratio = price-to-sales ratio. 7. Palantir's valuation is an unsustainable eyesore The final piece of the puzzle that explains why Palantir stock can plunge 60% (or more) is its valuation.

Reinet Investments SAC plunged on Friday after the Luxembourg-based company agreed to sell its stake in Pension Insurance Corp. Group Ltd. at a price that at least one analyst said undervalues the UK ...